|
Philadelphia, PA, Thursday, February 04, 2010: Hemispherx Biopharma, Inc. (NYSE Amex: HEB) (the “Company”), announced today the appointments of Dr. Christopher Cavalli and Mr. Robert Fidanza.
Dr. Cavalli served as Senior Director of Manufacturing Operations at Cytogen Corporation from 2006 until 2009, where he was responsible for the manufacture of Cytogen’s three commercial products. From 1999 until 2006, he worked at Discovery Laboratories, first as Associate Director of Analytical Services and ultimately as Senior Director of Analytical and Technical Services. In these roles he was responsible for Quality Control and Process Development. Dr. Cavalli received a Ph.D. in Chemistry from Temple University in Philadelphia, PA. Dr. Cavalli will be joining Hemispherx as Director of Quality Control in its New Brunswick, NJ facility.
Mr. Fidanza has 30 years of pharmaceutical experience, including the position of QA Director at Schering Plough. He provided quality oversight for various commercial products and has also directed the advancement of compounds through various stages of clinical development. He has designed, implemented and directed the execution of quality systems in GMP, GCP and GLP environments. He served as Chairman of the Board of the NJ Pharmaceutical Quality Control Association. Mr. Fidanza’s position will be Director of Quality Assurance in Hemispherx’s New Brunswick, NJ facility.
Dr. William Carter, Chairman and CEO of Hemispherx Biopharma, Inc. commented, “Dr. Cavalli’s and Mr. Fidanza’s combined experience and expertise greatly strengthen the manufacturing depth of our commercialized natural interferon product Alferon N Injection® and our experimental therapeutic Ampligen®, which is being developed in a number of clinical settings including as a potential vaccine enhancement and as a potential treatment for chronic fatigue syndrome”.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.
|
|
Contact:
Hemispherx Biopharma, Inc.,
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6369
HEB's Web Site: www.hemispherx.net
|
|
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company’s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen® and Alferon® LDO are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection® do not imply that the product will ever be specifically approved commercially for these other treatment indications.
|
